A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activity
Open Access
- 22 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 123 (4), 542-555
- https://doi.org/10.1038/s41416-020-0889-4
Abstract
Background AKT, a critical effector of the phosphoinositide 3-kinase (PI3K) signalling cascade, is an intensely pursued therapeutic target in oncology. Two distinct classes of AKT inhibitors have been in clinical development, ATP-competitive and allosteric. Class-specific differences in drug activity are likely the result of differential structural and conformational requirements governing efficient target binding, which ultimately determine isoform-specific potency, selectivity profiles and activity against clinically relevant AKT mutant variants. Methods We have carried out a systematic evaluation of clinical AKT inhibitors using in vitro pharmacology, molecular profiling and biochemical assays together with structural modelling to better understand the context of drug-specific and drug-class-specific cell-killing activity. Results Our data demonstrate clear differences between ATP-competitive and allosteric AKT inhibitors, including differential effects on non-catalytic activity as measured by a novel functional readout. Surprisingly, we found that some mutations can cause drug resistance in an isoform-selective manner despite high structural conservation across AKT isoforms. Finally, we have derived drug-class-specific phosphoproteomic signatures and used them to identify effective drug combinations. Conclusions These findings illustrate the utility of individual AKT inhibitors, both as drugs and as chemical probes, and the benefit of AKT inhibitor pharmacological diversity in providing a repertoire of context-specific therapeutic options.Keywords
Funding Information
- Cancer Research UK (A21773, CRC553X, A21773, A21773, C16420/A18066, A21773, C1060/A16464, A21773)
- RMH neuro-oncology research fund
- RCUK | Biotechnology and Biological Sciences Research Council (BB/M006174/1)
- Barts and The London Charity
This publication has 35 references indexed in Scilit:
- Pharmacodynamic Study of Miransertib in Individuals with Proteus SyndromeAmerican Journal of Human Genetics, 2019
- Capivasertib Active against AKT1-Mutated CancersCancer Discovery, 2019
- AKT Inhibition in Solid Tumors With AKT1 MutationsJournal of Clinical Oncology, 2017
- Maximising the potential of AKT inhibitors as anti-cancer treatmentsPharmacology & Therapeutics, 2016
- AKT in cancer: new molecular insights and advances in drug developmentBritish Journal of Clinical Pharmacology, 2016
- Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)International Journal of Oncology, 2015
- Clinical Trial Results from the Subgroup of Lymphoma/CLL in a Phase 1 Study of ARQ 092, a Novel Pan AKT-InhibitorBlood, 2015
- Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT InhibitorsMolecular Cancer Therapeutics, 2015
- PI3K and cancer: lessons, challenges and opportunitiesNature Reviews Drug Discovery, 2014
- A transforming mutation in the pleckstrin homology domain of AKT1 in cancerNature, 2007